10-Q: Hyperfine Reports Q1 2025 Results: Revenue Declines Amidst Cost-Cutting Efforts

Hyperfine's Q1 2025 revenue decreased due to lower device sales, despite cost-cutting measures and international expansion efforts.

Summary

• Hyperfine, Inc. reported its financial results for the first quarter of 2025.
• Revenue decreased to $2.1 million, compared to $3.3 million in Q1 2024, primarily due to lower device sales.
• The company sold 6 Swoop system units in Q1 2025, down from 13 units in Q1 2024.
• Despite the revenue decline, the average selling price of devices increased.
• The company implemented an organizational restructuring in January 2025, resulting in the termination of approximately 14% of its global workforce.
• This restructuring is expected to decrease costs and create a more streamlined organization.
• Hyperfine incurred up to $400 thousand in costs related to the restructuring, primarily for severance.
• Research and development expenses decreased by 9.6% to $5.0 million.
• General and administrative expenses decreased by 5.0% to $4.2 million.
• Sales and marketing expenses increased by 26.7% to $2.5 million.
• The net loss for Q1 2025 was $9.4 million, compared to $9.8 million in Q1 2024.
• As of March 31, 2025, Hyperfine had cash and cash equivalents of $33.1 million.
• The company believes its existing cash and cash equivalents, along with proceeds from product and service sales, will enable it to conduct planned operations for at least the next 12 months.
• Hyperfine is expanding its commercial focus beyond critical care to include emergency departments, neurology clinics, and neurology offices.
• The company is also pursuing international expansion in Canada, Europe, Australia, and New Zealand.
• Hyperfine received CE Mark and UKCA Mark approval for the latest AI-powered Swoop system software.
• The company is continuing its research partnership with the Bill & Melinda Gates Foundation (BMGF) to develop a scalable approach to measuring neurodevelopment via low-field MRI in low-to-middle income countries.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to decreased revenue and continued net losses, although cost-cutting measures and recent capital raises provide some optimism. The Nasdaq listing warning adds further negative pressure.

Positives

• The average selling price of devices increased.
• Service revenue increased due to a larger device install base.
• Research and development expenses decreased by 9.6% to $5.0 million.
• General and administrative expenses decreased by 5.0% to $4.2 million.
• The company received CE Mark and UKCA Mark approval for the latest AI-powered Swoop system software.
• Hyperfine is expanding its commercial focus and pursuing international expansion.
• The company is continuing its research partnership with the Bill & Melinda Gates Foundation (BMGF) with an additional $3.4 million grant.
• Change in fair value of warrant liabilities for the three months ended March 31, 2025 represented a gain of $1.6 million.

Negatives

• Revenue decreased to $2.1 million, compared to $3.3 million in Q1 2024.
• The company sold 6 Swoop system units in Q1 2025, down from 13 units in Q1 2024.
• The net loss for Q1 2025 was $9.4 million.
• The company implemented an organizational restructuring in January 2025, resulting in the termination of approximately 14% of its global workforce.
• The company incurred up to $400 thousand in costs related to the restructuring, primarily for severance.
• Interest income decreased by $0.5 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024.

Risks

• The company has incurred significant cash burn and recurring net losses.
• The company's ability to access capital when needed is not assured.
• Failure to maintain the listing of Class A common stock on Nasdaq could seriously harm the liquidity of shares and the ability to raise capital.
• The company relies on a single source manufacturer and single source suppliers for the supply of its products.
• The company is subject to risks and uncertainties caused by events with significant geopolitical and macroeconomic impacts, including, but not limited to, the conflicts in Ukraine and the Middle East, inflation, tariffs and actions taken to counter such impacts.

Future Outlook

Hyperfine expects its existing cash and cash equivalents, together with proceeds from the sales of its products and services, will enable it to conduct its planned operations for at least the next 12 months. The company plans to expand its commercial focus and pursue international expansion.

Management Comments

• Management believes the proceeds from recent offerings described herein, future offerings, and the Companys anticipated revenue, provides an opportunity to continue as a going concern.

Industry Context

The demand for MR imaging has been increasing due to the aging population and the rising prevalence of neurological, neurodegenerative, and cardiovascular conditions, recent approval of new Alzheimers medications, as well as the trends towards decentralized healthcare in mature, as well as lowand middle-income countries. Healthcare professionals and insurers recognize imaging as an effective, non-invasive diagnostic tool for evaluation and ongoing monitoring. The Swoop system is the next generation brain imaging device designed to increase access to MRI in a cost-effective manner.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A thorough comparison would require benchmarking against competitors like Siemens Healthineers, GE Healthcare, and Philips Healthcare, considering factors such as revenue growth, R&D spending as a percentage of revenue, and market share in the portable MRI segment.
• Additionally, comparing Hyperfine's financial metrics to those of other emerging growth companies in the medical device industry would provide valuable context.

Related Party Transactions

• The Company utilizes and subleases office and lab space in Connecticut, which is being leased from an unrelated landlord by 4Catalyzer Corporation (4C), which is owned by a related party.
• The Company pays rent to 4C on a month-to-month basis.
• Hyperfine entered into a Master Services Agreement (the Master Services Agreement) with 4C effective as of July 7, 2021 pursuant to which Hyperfine may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and continued net losses.
• Employees may be affected by the organizational restructuring and workforce reduction.
• Customers may benefit from the company's continued investment in product development and commercial expansion.
• The company's ability to maintain its Nasdaq listing is crucial for investor confidence.

Next Steps

• The company needs to regain compliance with Nasdaq's minimum bid price requirement by October 27, 2025.
• Hyperfine plans to continue investing in the development of its products and services.
• The company will focus on commercial expansion and international growth.
• Hyperfine will continue its research partnership with the Bill & Melinda Gates Foundation (BMGF).

Key Dates

Keywords

Hyperfine, Swoop system, MRI, Ultra-low-field, Portable MR Imaging, Financial results, Q1 2025, Revenue, Net loss, Restructuring, AI, BMGF, FDA, CE Mark, UKCA Mark